Cancer
Malignant Liver Neoplasm
CI-CAN-00003177Explore in graph →
Top-level906 active trials14 approved drugs17 evidence items
Loading cancer entity…
Cancer
CI-CAN-00003177Explore in graph →
Clinical trials
4,120 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (459)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06968195 | Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma | suspended | Phase 1 | 24 | Roswell Park Cancer InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06050252 | Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery | suspended | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Sep 4, 2026 |
| clinicaltrials |
| NCT06620302 | Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma | suspended | Phase 1 / Phase 2 | 81 | Children's Oncology GroupNETWORK | 1 | Aug 24, 2026 | clinicaltrials |
| NCT05791448 | AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease | suspended | Phase 1 | 36 | University of Southern CaliforniaOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT05377827 | Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies | suspended | Phase 1 | 6 | Washington University School of MedicineOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT06405061 | Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular Carcinoma | suspended | Phase 2 | 40 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT04955808 | Biospecimen Collection in Identifying Genetic Changes in Patients With Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery | suspended | — | 2,400 | National Cancer Institute (NCI)NIH | 1 | May 13, 2026 | clinicaltrials |
| NCT06653023 | Universal CAR-T Cells (REVO-UWD-03) for Advanced Hepatocellular Carcinoma and Lung Cancer(Wondercel-UWD3) | suspended | Early Phase 1 | 60 | Wondercel Biotech (ShenZhen)INDUSTRY | 1 | May 7, 2026 | clinicaltrials |
| NCT04929015 | Peritoneal Carcinomatosis Leveraging ctDNA Guided Treatment in GI Cancer Study (PERICLES Study) | suspended | N/A | 30 | Rutgers, The State University of New JerseyOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT05033522 | Immunotherapy for Advanced Liver Cancer(ALIVE) | suspended | Phase 2 / Phase 3 | 150 | Mirror Biologics, Inc.INDUSTRY | 2 | Oct 23, 2025 | clinicaltrials |
| NCT05603572 | KAT-101 in Subjects With Hepatocellular Carcinoma (HCC) | suspended | Phase 1 / Phase 2 | 148 | Primocure PharmaINDUSTRY | 1 | Jun 5, 2025 | clinicaltrials |
| NCT04268888 | Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC(TACE-3) | suspended | Phase 2 / Phase 3 | 522 | The Clatterbridge Cancer Centre NHS Foundation TrustOTHER | 2 | Feb 26, 2025 | clinicaltrials |
| NCT02935478 | Bariatric Embolization of Arteries in Obese Patients With HCC to Allow Salvage Liver Transplantation | suspended | N/A | 8 | St. Louis UniversityOTHER | 1 | Feb 6, 2025 | clinicaltrials |
| NCT04506983 | GPC3-CAR-T Cells for the Hepatocellular Carcinoma | suspended | Phase 1 | 12 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Feb 14, 2022 | clinicaltrials |
| NCT03990974 | Postoperative Antimicrobial Prophylaxis Versus Placebo for Infection Prevention in HCC After Liver Resection(HCC) | suspended | Phase 3 | 458 | Sun Yat-sen UniversityOTHER | 1 | Mar 25, 2020 | clinicaltrials |
| NCT03779100 | Lenvatinib Plus PD-1 Antibody for Unresectable ICC | suspended | Phase 2 | 25 | Shi MingOTHER | 1 | Jan 28, 2019 | clinicaltrials |
| NCT02026362 | Multiple Antigen Specific Cell Therapy (MASCT) for Hepatocellular Carcinoma(HCC) Patients After Radical Resection or Radio Frequency Ablation(RFA).(HCC DC CTL) | suspended | Phase 1 / Phase 2 | 100 | HRYZ Biotech Co.INDUSTRY | 1 | Oct 18, 2017 | clinicaltrials |
| NCT00909558 | Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer | suspended | Phase 1 | 24 | Envita Medical Center, Inc.INDUSTRY | 1 | Feb 24, 2010 | clinicaltrials |
Data updated 14 days agoSource updated Sep 15, 2026source: clinicaltrials